Jijo James, a top Johnson & Johnson executive, will succeed CVRx CEO Nadim Yared as the next chair of MDIC next summer.
Jijo James, chief medical officer at Johnson & Johnson, will take over the reigns as chair of the Medical Device Innovation Consortium next summer.
In a 24 September statement from the MDIC, the group said James would take his seat as chair of its...
A late-August batch of device classifications from the US FDA includes genetic tests from 23andMe, hand-held spinal surgery tools, and several IVDs.
Combination products are no longer fringe – they are the “new normal,” consultant Stephen O’Rourke told Medtech Insight. The EU has the expertise to handle the regulatory complexity, but only if connects the dots between silos. That’s the challenge, he said, and the opportunity.
The UK device regulator wants to align health institution device exemptions with its evolving policy of agile regulation of medtech in the British market. It asks stakeholders to complete a survey by Sept. 15.
An FDA panel has endorsed the use of dermal fillers for décolletage, but warned of patient safety concerns. The filler can cause complications with future imaging and pregnancy or breastfeeding, panelists said. Regulatory measures and patient studies are recommended for better outcomes.
